Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

501 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine.
Handa H, Cheong JW, Onishi Y, Iida H, Kobayashi Y, Kim HJ, Chiou TJ, Izutsu K, Tsukurov O, Zhou X, Faessel H, Yuan Y, Sedarati F, Faller DV, Kimura A, Wu SJ. Handa H, et al. Among authors: izutsu k. J Hematol Oncol. 2022 May 11;15(1):56. doi: 10.1186/s13045-022-01264-w. J Hematol Oncol. 2022. PMID: 35545778 Free PMC article. Clinical Trial.
Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS).
Oshima K, Takahashi W, Asano-Mori Y, Izutsu K, Takahashi T, Arai Y, Nakagawa Y, Usuki K, Kurokawa M, Suzuki K, Mitani K, Kanda Y. Oshima K, et al. Among authors: izutsu k. Ann Hematol. 2012 Oct;91(10):1533-9. doi: 10.1007/s00277-012-1487-1. Epub 2012 May 11. Ann Hematol. 2012. PMID: 22576311
A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.
Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H, Endo T, Terui Y, Iwaki N, Fukuhara N, Tatetsu H, Iida S, Ishikawa T, Shiibashi R, Izutsu K. Sekiguchi N, et al. Among authors: izutsu k. Cancer Sci. 2020 Sep;111(9):3327-3337. doi: 10.1111/cas.14561. Epub 2020 Jul 20. Cancer Sci. 2020. PMID: 32639651 Free PMC article. Clinical Trial.
Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
Ito A, Kim SW, Matsuoka KI, Kawakita T, Tanaka T, Inamoto Y, Toubai T, Fujiwara SI, Fukaya M, Kondo T, Sugita J, Nara M, Katsuoka Y, Imai Y, Nakazawa H, Kawashima I, Sakai R, Ishii A, Onizuka M, Takemura T, Terakura S, Iida H, Nakamae M, Higuchi K, Tamura S, Yoshioka S, Togitani K, Kawano N, Suzuki R, Suzumiya J, Izutsu K, Teshima T, Fukuda T. Ito A, et al. Among authors: izutsu k. Int J Hematol. 2020 Nov;112(5):674-689. doi: 10.1007/s12185-020-02960-4. Epub 2020 Aug 3. Int J Hematol. 2020. PMID: 32748216
Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Fukuhara N, Kinoshita T, Yamamoto K, Nagai H, Izutsu K, Yamamoto G, Bhargava P, Rajakumaraswamy N, Humeniuk R, Mathias A, Xing G, Fukui M, Tobinai K. Fukuhara N, et al. Among authors: izutsu k. Jpn J Clin Oncol. 2020 Dec 16;50(12):1395-1402. doi: 10.1093/jjco/hyaa153. Jpn J Clin Oncol. 2020. PMID: 32856068 Clinical Trial.
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.
Takezako N, Kosugi H, Matsumoto M, Iida S, Ishikawa T, Kondo Y, Ando K, Miki H, Matsumura I, Sunami K, Teshima T, Iwasaki H, Onishi Y, Kizaki M, Izutsu K, Maruyama D, Tobinai K, Ghori R, Farooqui M, Liao J, Marinello P, Matsuda K, Koh Y, Shimamoto T, Suzuki K. Takezako N, et al. Among authors: izutsu k. Int J Hematol. 2020 Nov;112(5):640-649. doi: 10.1007/s12185-020-02953-3. Epub 2020 Sep 19. Int J Hematol. 2020. PMID: 32949374
Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, Choi I, Humphrey K, Kim SY, Okubo S, Ogawa N, Nishimura Y, Salem AH, Maruyama D. Izutsu K, et al. Int J Hematol. 2021 Mar;113(3):370-380. doi: 10.1007/s12185-020-03024-3. Epub 2020 Oct 23. Int J Hematol. 2021. PMID: 33094474 Clinical Trial.
The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.
Nozaki K, Maruyama D, Maeshima AM, Tajima K, Itami J, Shichijo T, Yuda S, Suzuki T, Toyoda K, Yamauchi N, Makita S, Fukuhara S, Munakata W, Kobayashi Y, Taniguchi H, Izutsu K, Tobinai K. Nozaki K, et al. Among authors: izutsu k. Eur J Haematol. 2021 Feb;106(2):213-220. doi: 10.1111/ejh.13539. Epub 2020 Nov 6. Eur J Haematol. 2021. PMID: 33098704 Free PMC article.
501 results